新型冠状病毒肺炎中的细胞因子风暴与免疫调节
Cytokine Storm and Immunomodulation in COVID-19.
作者信息
Rangappa Pradeep
机构信息
Department of Critical Care Medicine, Columbia Asia, Bengaluru, Karnataka, India.
出版信息
Indian J Crit Care Med. 2021 Nov;25(11):1288-1291. doi: 10.5005/jp-journals-10071-24029.
Abstract
UNLABELLED
COVID-19 has become a major pandemic in recent times. The exact pathophysiology and understanding of cytokine storm and immunomodulation are evolving. Various cytokines have been implicated in the pathophysiology of COVID-19. Immunosuppressant immunomodulators like steroids, canakinumab, anakinra, tocilizumab, sarilumab, baricitinib, ruxolitinib, bevacizumab, and itolizumab have been tried. Immunostimulant immunomodulators like interferons (IFNs) and Mycobacterium w (Mw) have also been repurposed. Considering the role of multiple cytokines implicated in COVID-19, molecules working on the majority of the targets, may hold a promising future prospect.
HOW TO CITE THIS ARTICLE
Rangappa P. Cytokine Storm and Immunomodulation in COVID-19. Indian J Crit Care Med 2021;25(11):1288-1291.
摘要
未标注
近期，新型冠状病毒肺炎（COVID-19）已成为一场重大的大流行病。细胞因子风暴和免疫调节的确切病理生理学及相关认识正在不断发展。多种细胞因子与COVID-19的病理生理学有关。已尝试使用免疫抑制剂免疫调节剂，如类固醇、卡那单抗、阿那白滞素、托珠单抗、沙瑞鲁单抗、巴瑞替尼、芦可替尼、贝伐单抗和依托珠单抗。免疫刺激剂免疫调节剂，如干扰素（IFN）和结核分枝杆菌w（Mw）也已被重新利用。考虑到多种细胞因子在COVID-19中的作用，作用于大多数靶点的分子可能具有广阔的未来前景。
如何引用本文
兰加帕P。COVID-19中的细胞因子风暴和免疫调节。《印度重症监护医学杂志》2021年；25（11）：1288 - 1291。
相似文献
1
Cytokine Storm and Immunomodulation in COVID-19.新型冠状病毒肺炎中的细胞因子风暴与免疫调节
Indian J Crit Care Med. 2021 Nov;25(11):1288-1291. doi: 10.5005/jp-journals-10071-24029.
2
Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center.英夫利昔单抗在新冠病毒感染所致急性呼吸窘迫综合征患者中的超说明书用药：我们在一家专门的新冠治疗中心的临床经验
Indian J Crit Care Med. 2021 Apr;25(4):467-469. doi: 10.5005/jp-journals-10071-23787.
3
Pharmaco-Immunomodulatory Therapy in COVID-19.COVID-19 的药物免疫调节治疗。
Drugs. 2020 Sep;80(13):1267-1292. doi: 10.1007/s40265-020-01367-z.
4
Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm.靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）诱导的细胞因子风暴管理中的特定检查点
Life (Basel). 2022 Mar 25;12(4):478. doi: 10.3390/life12040478.
5
Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations.新型冠状病毒肺炎（COVID-19）中的细胞因子风暴：专家管理考量
Indian J Crit Care Med. 2020 Jun;24(6):429-434. doi: 10.5005/jp-journals-10071-23415.
6
Multiple Peaked Cytokine Storm: Is Multiple Exposures to the COVID-19 Virus a Possible Cause?多峰细胞因子风暴：多次接触新冠病毒是否为可能的病因？
Indian J Crit Care Med. 2021 Apr;25(4):463-464. doi: 10.5005/jp-journals-10071-23786.
7
Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.比较免疫调节疗法治疗 2019 年冠状病毒病细胞因子风暴的生存分析。
Chest. 2021 Mar;159(3):933-948. doi: 10.1016/j.chest.2020.09.275. Epub 2020 Oct 17.
8
Tocilizumab and COVID-19.托珠单抗与新型冠状病毒肺炎
Indian J Crit Care Med. 2020 Sep;24(9):741-743. doi: 10.5005/jp-journals-10071-23608.
9
Present and future treatment strategies for coronavirus disease 2019.2019年冠状病毒病的当前及未来治疗策略
Futur J Pharm Sci. 2021;7(1):84. doi: 10.1186/s43094-021-00238-y. Epub 2021 Apr 9.
10
Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.托珠单抗用于治疗新冠病毒感染细胞因子释放综合征：两个中心的回顾性研究
Indian J Crit Care Med. 2020 Sep;24(9):771-776. doi: 10.5005/jp-journals-10071-23566.
引用本文的文献
1
Efficacy and safety of tofacitinib on COVID-19 patients: A systematic review and meta-analysis.托法替布对新冠病毒肺炎患者的疗效和安全性：一项系统评价与荟萃分析。
Heliyon. 2024 Sep 20;10(19):e38229. doi: 10.1016/j.heliyon.2024.e38229. eCollection 2024 Oct 15.
2
COVID-19 Clinical Features and Outcomes in Elderly Patients during Six Pandemic Waves.六次疫情浪潮期间老年患者的新冠病毒疾病临床特征及转归
J Clin Med. 2022 Nov 17;11(22):6803. doi: 10.3390/jcm11226803.
3
A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients.一项双盲、多中心、双臂随机、安慰剂对照的III期临床研究，旨在评估在中度至重度COVID-19患者中，将胸腺肽α1作为现有标准治疗的附加治疗的有效性和安全性。
Indian J Crit Care Med. 2022 Aug;26(8):913-919. doi: 10.5005/jp-journals-10071-24298.
4
The impact of immune dysfunction on perioperative complications in surgical COVID-19 patients: an imperative for early immunonutrition.免疫功能障碍对COVID-19手术患者围手术期并发症的影响：早期免疫营养的必要性。
Patient Saf Surg. 2022 Apr 1;16(1):14. doi: 10.1186/s13037-022-00323-y.
本文引用的文献
1
Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations.新型冠状病毒肺炎（COVID-19）中的细胞因子风暴：专家管理考量
Indian J Crit Care Med. 2020 Jun;24(6):429-434. doi: 10.5005/jp-journals-10071-23415.
2
Canakinumab in a subgroup of patients with COVID-19.卡那单抗用于新冠肺炎患者亚组。
Lancet Rheumatol. 2020 Aug;2(8):e457-ee458. doi: 10.1016/S2665-9913(20)30167-3. Epub 2020 Jun 4.
3
Anakinra for severe forms of COVID-19: a cohort study.阿那白滞素用于重症新型冠状病毒肺炎：一项队列研究。
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
4
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
5
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19.托珠单抗治疗 COVID-19 机械通气患者。
Clin Infect Dis. 2021 Jul 15;73(2):e445-e454. doi: 10.1093/cid/ciaa954.
6
Is a "Cytokine Storm" Relevant to COVID-19?“细胞因子风暴”与新冠病毒病有关吗？
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154. doi: 10.1001/jamainternmed.2020.3313.
7
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.COVID-19：最新可用药物和 SARS-CoV-2 疗法综述。凝血与炎症相互作用。
Virus Res. 2020 Sep;286:198070. doi: 10.1016/j.virusres.2020.198070. Epub 2020 Jun 20.
8
The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.COVID-19 中的细胞因子风暴：趋化因子/趋化因子受体系统的参与概述。
Cytokine Growth Factor Rev. 2020 Jun;53:25-32. doi: 10.1016/j.cytogfr.2020.05.003. Epub 2020 May 11.
9
p38 MAPK inhibition: A promising therapeutic approach for COVID-19.p38 MAPK 抑制：COVID-19 的一种有前景的治疗方法。
J Mol Cell Cardiol. 2020 Jul;144:63-65. doi: 10.1016/j.yjmcc.2020.05.007. Epub 2020 May 16.
10
COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.COVID-19：干扰素的发病机制、细胞因子风暴和治疗潜力。
Cytokine Growth Factor Rev. 2020 Jun;53:66-70. doi: 10.1016/j.cytogfr.2020.05.002. Epub 2020 May 7.
Zotero 插件